The Clopidogrel Dilemma in Thromboprophylaxis Following Total Joint Arthroplasty

Although the incidence of venous thromboembolism (VTE) following total joint arthroplasty (TJA) has decreased with the use of multimodal thromboprophylaxis, there are still higher-risk patients who may need extra care. While aspirin has become the leading agent for chemoprophylaxis in clinical practice, the management of patients undergoing TJA who have complex cardiovascular comorbidities has introduced new questions about the role of alternative antiplatelet agents, particularly clopidogrel. Clopidogrel, a P2Y12 receptor antagonist, has long been established as a potent inhibitor of platelet aggregation, and is primarily used for secondary prevention in patients who have experienced coronary artery disease, stroke, or peripheral vascular disease. As surgical volumes increase in an aging and comorbid population, it is increasingly common for orthopaedic surgeons to encounter patients for whom the discontinuation of clopidogrel poses higher cardiac risks. The perioperative management of such patients requires nuanced judgment—balancing atherothrombotic protection against bleeding complications. The study by Telang et al. makes an important contribution by systematically examining the outcomes of clopidogrel monotherapy used for VTE prophylaxis following primary TJA. Using a large national database and robust propensity-score matching, the authors compared outcomes of patients who received either clopidogrel or aspirin following elective TJA. Their findings suggest that while thromboembolic outcomes—including deep vein thrombosis, pulmonary embolism, and myocardial infarction—were similar between the groups, clopidogrel was associated with a modest but significant increase in the rates of postoperative bleeding complications, including transfusion and acute anemia. From a clinical perspective, these results reinforce the delicate balance that is inherent in perioperative antiplatelet management. The 1.69-fold increase in the risk of transfusion and 1.13-fold increase in the risk of acute anemia, although not very high, are clinically meaningful. Allogeneic transfusion itself has been linked to higher postoperative morbidity, including infection and prolonged hospitalization. Yet, it is equally important to recognize that thromboembolic protection—particularly in patients with prior cardiovascular events—cannot be compromised. This underscores the need for interdisciplinary decision-making, involving both orthopaedic and cardiovascular specialists, to tailor postoperative antithrombotic strategies on the basis of patient-specific risks rather than rigid protocols. The findings also invite reflection on the evolving landscape of pharmacologic prophylaxis in arthroplasty. The cardiovascular literature increasingly supports clopidogrel monotherapy as a viable alternative to aspirin following coronary interventions, suggesting potentially comparable efficacy in platelet inhibition with a similar or reduced risk of gastrointestinal bleeding. However, the surgical context in orthopaedics is distinct and different, particularly in major orthopaedic procedures, where surgical soft-tissue and bone trauma and postoperative early mobilization may amplify the bleeding consequences of potent antiplatelet therapy. One might consider whether a staged approach to postoperative antithrombotic therapy may yield a more favorable risk-benefit ratio. For example, initiating bridging aspirin and/or low-molecular-weight heparin monotherapy during the early postoperative period, when bleeding risk peaks, and transitioning to clopidogrel several days later once hemostasis is deemed secure, may provide adequate thromboembolic and atherothrombotic protection while minimizing transfusion requirements. Nonetheless, criteria on the timing of the transition to clopidogrel are not presented in this study or established in the literature. This hypothesis merits further prospective evaluation, ideally through multidisciplinary trials that account for cardiac indications and perioperative timing. Despite the strengths of this study, the evidence for clopidogrel use in arthroplasty remains limited, with few large-scale or prospective studies. The present analysis highlights the logistical challenges of investigating a relatively small, high-risk subgroup within the arthroplasty population. Nonetheless, by quantifying the bleeding risk associated with postoperative clopidogrel use, the authors provide valuable real-world data that can guide perioperative decision-making and inform shared discussions with patients about balancing cardiovascular safety and surgical recovery. In conclusion, clopidogrel monotherapy appears to offer thromboembolic protection comparable with that of aspirin following total joint arthroplasty but at the expense of higher bleeding-related morbidity. For patients with notable cardiovascular risk who require ongoing antiplatelet therapy, the early postoperative resumption of clopidogrel should be carefully individualized, coordinated with cardiology consultation, and potentially delayed until hemostatic stability is achieved. The future of thromboprophylaxis in TJA will likely depend on increasingly personalized regimens that integrate orthopaedic and cardiovascular perspectives to optimize both surgical and medical outcomes.